A single dose, crossover comparative exposure pharmacokinetic (PK) trial of metoclopramide nasal spray to demonstrate bioequivalence of Gimoti in healthy volunteers

Trial Profile

A single dose, crossover comparative exposure pharmacokinetic (PK) trial of metoclopramide nasal spray to demonstrate bioequivalence of Gimoti in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Metoclopramide (Primary)
  • Indications Diabetic gastroparesis
  • Focus Pharmacokinetics; Registrational
  • Sponsors Evoke Pharma
  • Most Recent Events

    • 07 Mar 2018 According to an Evoke Pharma media release, the Company has confirmed the proposed dose for women to be submitted in the NDA, based on the results of this trial.
    • 07 Mar 2018 Status changed from active, no longer recruiting to completed, according to an Evoke Pharma media release.
    • 15 Feb 2018 According to an Evoke Pharma media release, the company plans to submit its NDA for a female-only indication based on a dose in women with equivalent exposure to Reglan Tablets and will submit supporting efficacy and safety data from this and other trial (see profile 240919) specifically for women, at doses similar or lower than the dose to be proposed in the NDA. The Company expects to file the Gimoti NDA in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top